Intra-Cellular Therapies, Inc. (ITCI) Surges to 52-Week High, Is Now Top Performer

March 15, 2018 - By Hazel Jackson

Investors sentiment increased to 2.77 in Q3 2017. Its up 1.91, from 0.86 in 2017Q2. It increased, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported.
Clough Capital Prtn Limited Partnership accumulated 658,750 shares. Bnp Paribas Arbitrage Sa stated it has 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Schwab Charles Investment Mgmt Inc owns 133,183 shares or 0% of their US portfolio. Tower Research Capital Ltd Liability Co (Trc) has 4,091 shares for 0.01% of their portfolio. Laurion Capital Mngmt Lp owns 550,000 shares. Premier Asset Ltd Liability Company owns 18,429 shares. 10,000 were reported by Gemmer Asset Ltd Liability. Soros Fund Ltd Limited Liability Company stated it has 114,000 shares. Hbk Investments Lp has 300,000 shares for 0.04% of their portfolio. Geode Cap Limited Liability Corp holds 337,189 shares or 0% of its portfolio. Hillhouse Cap Management has invested 0.26% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Metropolitan Life Company Ny has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). 30,965 are owned by Nationwide Fund Advsrs. Perceptive Limited Liability Com has invested 0.56% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Baker Bros Advisors Limited Partnership accumulated 609,166 shares.

Since September 29, 2017, it had 3 insider purchases, and 10 sales for $9.93 million activity. 49,700 shares were sold by Hineline Lawrence J., worth $995,165 on Thursday, February 15. On Wednesday, January 3 Vanover Kimberly E. sold $20,583 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 1,185 shares. Shares for $459,765 were sold by Halstead Michael. $105,630 worth of stock was sold by LERNER RICHARD A on Monday, December 11. On Friday, September 29 the insider Alafi Christopher D bought $4.00 million. Mates Sharon sold 11,257 shares worth $192,270.

The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) hit a new 52-week high and has $27.73 target or 9.00 % above today’s $25.44 share price. The 7 months bullish chart indicates low risk for the $1.39 billion company. The 1-year high was reported on Mar, 15 by If the $27.73 price target is reached, the company will be worth $125.19 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.20% or $0.05 during the last trading session, reaching $25.44. About 165,044 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since March 15, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on May, 9. They expect $-0.65 earnings per share, down 4.84 % or $0.03 from last year’s $-0.62 per share. After $-0.56 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts 16.07 % negative EPS growth.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 13 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Intra-Cellular Therapies had 44 analyst reports since August 6, 2015 according to SRatingsIntel. Cowen & Co maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) rating on Friday, September 8. Cowen & Co has “Buy” rating and $27.0 target. The rating was downgraded by SunTrust on Thursday, September 29 to “Neutral”. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, November 6. The company was upgraded on Wednesday, August 30 by Ladenburg. Cantor Fitzgerald maintained it with “Buy” rating and $2900 target in Wednesday, August 9 report. On Friday, August 7 the stock rating was upgraded by Zacks to “Sell”. The company was maintained on Wednesday, March 9 by JMP Securities. As per Wednesday, August 9, the company rating was maintained by Piper Jaffray. Cowen & Co maintained the stock with “Buy” rating in Thursday, March 1 report. The rating was upgraded by JMP Securities on Thursday, August 24 to “Market Outperform”.

More recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: which released: “Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial …” on February 22, 2018. Also published the news titled: “Premarket analyst action – healthcare” on February 26, 2018.‘s news article titled: “Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial …” with publication date: March 01, 2018 was also an interesting one.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $1.39 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.